This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Labcorp (LH) to Boost Clinical Diagnostics With New Deal
by Zacks Equity Research
The recent deal will augment Labcorp's (LH) laboratory services network and expand access to the company's high-quality clinical laboratory services.
Neuronetics' (STIM) FDA-Cleared NeuroStar to Aid in Depression
by Zacks Equity Research
Neuronetics (STIM) announces the FDA's approval of NeuroStar Advanced Therapy, which is likely to aid in the treatment of depression in adolescents by acting as a supplement.
Here's Why Cencora (COR) is a Strong Value Stock
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Here's Why Investors Should Hold Teladoc (TDOC) Stock Now
by Zacks Equity Research
Teladoc's (TDOC) Integrated Care business is expected to gain from margin expansion and improving chronic care program enrollment.
McKesson (MCK) Hits 52-Week High: What's Driving the Stock?
by Zacks Equity Research
Investors are optimistic about McKesson's (MCK) strength in its Biologics business.
Walgreens Boots (WBA) Q2 Earnings Top Estimates, EPS View Down
by Zacks Equity Research
Walgreens Boots' (WBA) comparable pharmacy sales in the fiscal second quarter benefited from higher branded drug inflation and strong execution in pharmacy services.
GE HealthCare's (GEHC) PVA to Aid in Capturing Prostate Volume
by Zacks Equity Research
GE HealthCare (GEHC) announces the launch of Prostate Volume Assist AI-enabled urology software feature, which is likely to boost prostate imaging, capture prostate volume and increase workflow.
3 Reasons to Retain Inogen (INGN) Stock in Your Portfolio
by Zacks Equity Research
Expanding product portfolio and high prospects for POC raise optimism for Inogen (INGN) stock.
Here's Why Investors Should Retain STERIS (STE) Stock for Now
by Zacks Equity Research
Investors are optimistic about STERIS (STE) on strong Healthcare business performance and raised 2024 guidance.
Are Medical Stocks Lagging Artivion (AORT) This Year?
by Zacks Equity Research
Here is how Artivion (AORT) and Cencora (COR) have performed compared to their sector so far this year.
Zacks.com featured highlights include General Motors, Cardinal Health, Cencora, Alta Equipment Group and Asbury Automotive
by Zacks Equity Research
General Motors, Cardinal Health, Cencora, Alta Equipment Group and Asbury Automotive are part of the Zacks Screen of the Week article.
Accuray's (ARAY) CyberKnife Improves Prostate Cancer Treatment
by Zacks Equity Research
Accuray (ARAY) announces the latest data that supports the use of its CyberKnife System in the treatment of recurrent prostate cancer with stereotactic body radiation therapy.
Abbott's (ABT) Assert-IQ Cardiac Monitor Receives CE Mark
by Zacks Equity Research
Abbott's (ABT) Assert-IQ ICM enables regular monitoring for abnormal heart rhythms, as well as technologies to improve data management and workflow.
Here's Why You Should Buy Zimmer Biomet (ZBH) Stock Now
by Zacks Equity Research
Investors are optimistic about Zimmer Biomet (ZBH), led by expansion in the knee business and recovery across the business.
DexCom (DXCM) Hits 52-Week High: What's Driving the Stock?
by Zacks Equity Research
Investors are optimistic about DexCom's (DXCM) strong product portfolio.
Stryker's (SYK) Latest Launch to Streamline Procedural Workflows
by Zacks Equity Research
Stryker's (SYK) latest addition to its Gamma legacy is expected to streamline workflows and enhance usability.
Why Cencora (COR) is a Top Growth Stock for the Long-Term
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
5 Broker-Loved Stocks That Hold Promise Despite Volatility
by Maharathi Basu
We believe that stocks like General Motors (GM), Cardinal Health (CAH), Cencora (COR), Alta Equipment (ALTG) and Asbury (ABG) should be on an investor's watchlist.
Reasons to Add Cencora (COR) Stock in Your Portfolio Now
by Zacks Equity Research
Cencora (COR) continues to gain traction from the robust U.S. Healthcare Solutions segment. However, stiff competition is a woe.
Three Reasons to Retain Avantor (AVTR) Stock in Your Portfolio
by Zacks Equity Research
Avantor's (AVTR) strong product portfolio raises optimism about the stock.
Veeva Systems' (VEEV) Vault EDC Witnesses Increasing Adoption
by Zacks Equity Research
Veeva Systems' (VEEV) Vault EDC is likely to enable companies to build a modern clinical data foundation.
Reasons to Add Veeva Systems (VEEV) to Your Portfolio Now
by Zacks Equity Research
Veeva's strong product demand and strategic deals raise optimism about the stock.
GE HealthCare (GEHC) to Sell IONIC's FDA-Cleared nCommand Lite
by Zacks Equity Research
GE HealthCare (GEHC) announces the FDA approval of IONIC Health's nCommand Lite technology, which it will distribute for multi-vendor, multi-modality remote operations purposes exclusively.
QIAGEN (QGEN) Unveils QIAstat-Dx Analyzer With Remote Access
by Zacks Equity Research
With QIAGEN's (QGEN) QIAstat-Dx Analyzer 2.0's integration of remote access, central and regional laboratories may work together efficiently, particularly when it comes to decentralized testing.
Beat the Market the Zacks Way: Micron Technology, American Eagle Outfitters, Cencora in Focus
by Santanu Roy
Our time-tested methodologies were at work to help investors navigate the market well last week. Here are some of our key performance data from the past three months.